Moderna reinforces its alliance in Spain. The American biotechnology company, which has an agreement in the country with Rovi Pharmaceutical Laboratories, plans to conclude 2022 by manufacturing 500 million doses of its anti-Covid-19 vaccine, as confirmed by Juan Carlos Gil, general director of Moderna in Spain and Portugal, to PlantaDoce.
So far, the company has manufactured just over 350 million doses of its vaccine against Covid-19 in Spain, which it has distributed to more than sixty countries. On a global scale, those 500 million translate into more than 800 million doses.
Some plans that in Spain are forged with the renewal of the agreement between Moderna and Rovi for ten more years to increase formulation, aseptic filling, inspection, labeling and packaging capabilities at Rovi’s facilities in Madrid, San Sebastián de los Reyes and Alcalá de Henares.
This new agreement includes establishing the production of Moderna’s Covid-19 vaccine in Rovi’s factories. Besides, the platform of the Spanish company can also be used to service future vaccines Moderna’s messenger RNA (mRNA) candidates.
The mRNA serves as a starting point for multiple new projects Moderna is working on. The biotech aspires to have a panrespiratory vaccine. “Respiratory viruses are the ones that cause the most deaths; When a patient is admitted to the hospital with a serious illness, what ultimately causes death is a respiratory condition,” explains Gil.
And from respiratory viruses to the bivalent influenza-Covid: presumably, at the end of 2023 Spain will be able to distribute a vaccine of this type with the seal of Moderna, which will be able to avoid hospitalizations and deaths.
Another of Moderna’s challenges is to find a vaccine capable of eradicating fifteen pathogens that the World Health Organization (WHO) considers more dangerous for public health. “By 2025 we want a vaccine to enter the clinical trial phase,” says the head of Moderna in Spain. Some of these diseases are malaria, Zika, dengue, tuberculosis, HIV, or Crimean-Congo hemorrhagic fever.
Moderna closed 2021 with a profit of 12.2 billion dollars
Moderna closed 2021 with a profit of 12.2 billion dollars, compared to the losses of 747 million dollars recorded in 2020. Moderna’s total revenue in 2021 was $18.471 million, up from $803 million in 2020. Of this total, product sales were $17.675 million, while in 2020 they were $200 million in 2020 .
Moderna believes that the Sars-Cov-2 virus will evolve into an endemic phase in 2022 and, as a result, the company expects sales to be higher in the second half than in the first half of the year.
In 2022, the company plans to further expand its business network through the establishment or activation of business subsidiaries in the following geographies: in Asia: Hong Kong, Malaysia, Singapore and Taiwan; and in Europe: Belgium, Denmark, the Netherlands, Norway, Poland and Sweden. Additionally, Moderna will continue to work with distributors or partners in other geographies.
–
